# COBRA SHIELD OCT Study

> **NCT02224235** · NA · TERMINATED · sponsor: **CeloNova BioSciences, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Stable Angina

## Interventions

- **DRUG:** Aspirin
- **DEVICE:** Resolute Integrity DES
- **DEVICE:** COBRA PzF
- **DRUG:** DAPT

## Key facts

- **NCT ID:** NCT02224235
- **Lead sponsor:** CeloNova BioSciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Inadequate enrollment
- **Last updated:** 2020-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224235, "COBRA SHIELD OCT Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02224235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*